AstraZeneca PLC (AZN.L)
3,485.50GBp
22 May 2013
91.00p (+2.68%)
3,394.50p
3,405.00p
3,487.50p
3,397.00p
4,025,298
2,478,533
3,487.50p
2,578.50p
AZN.L
About
Overall
| Beta: | 0.32 |
| Market Cap (Mil.): | £42,758.30 |
| Shares Outstanding (Mil.): | 1,251.39 |
| Dividend: | 122.26 |
| Yield (%): | 5.31 |
Financials
| AZN.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 11.47 | 34.93 | 35.13 |
| EPS (TTM): | 2.98 | -- | -- |
| ROI: | 15.60 | 19.47 | 18.83 |
| ROE: | 25.88 | 20.22 | 19.68 |
AstraZeneca closes in on site for new home in Cambridge
LONDON - AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just south of the English city the most likely site, property industry sources said.
AstraZeneca closes in on site for new home in Cambridge
* New research centre and corporate HQ to cost some $500 mln
AstraZeneca accelerates cancer drug testing
LONDON - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers on a promise to accelerate its oncology programs.
AstraZeneca accelerates cancer drug testing
* Final-stage studies on olaparib, selumetinib start in H2
Big drugmakers think small with nanomedicine deals
* Early-stage research but scientists see momentum building
FTSE steadies, weak corporate earnings weigh
LONDON, April 25 - Britain's top share index traded flat on Thursday, steadying after recent robust gains, with falls in stocks such as AstraZeneca and Unilever on weak corporate earnings pegging the market back.
AstraZeneca hit by generic drugs and Crestor shortfall
LONDON - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries took a heavy toll, underscoring the turnaround challenge facing Britain's second-largest drugmaker.
UPDATE 2-AstraZeneca hit by generic drugs and Crestor shortfall
* Q1 sales fall 13 pct to $6.39 bln vs consensus $6.51 bln
AstraZeneca gets U.S. subpoena over UK drug factory
LONDON - AstraZeneca said on Thursday it had received a subpoena from the U.S. Attorney's Office in Boston, Massachusetts, related to manufacturing standards at its Macclesfield facility in the north of England.
AstraZeneca gets U.S. subpoena over UK drug factory
LONDON, April 25 - AstraZeneca said on Thursday it had received a subpoena from the U.S. Attorney's Office in Boston, Massachusetts, related to manufacturing standards at its Macclesfield facility in the north of England.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
